Navigation Links
Intralink-Spine Inc. Awarded $750,000 Small Business Innovation Research Phase II Grant
Date:2/1/2010

GEORGETOWN, Texas, Feb. 1 /PRNewswire/ -- Intralink-Spine Inc. (ILS), a privately held medical device company focused on the treatment of degenerative disc disease and low back pain, announced today that it has been awarded a $750,000 Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) for pre-clinical studies of its NEXT technology.  

Dr. Thomas Hedman, Ph.D., Founder and CSO of ILS, commented: "Securing this grant enables us to complete pre-clinical testing and start First-in-Man clinical trials.  This grant also underscores the mounting enthusiasm for our unique injectable treatment for low back pain, which affects over 15 million people each year in the US alone."

The technology, NEXT (Nonsurgical EXogenous crosslink Therapy), is based on the body's natural response to heal instability and degradation of the spinal disc.  The NEXT device is designed to immediately strengthen and stabilize the disc, reducing disc bulge and pain without the costs and risks associated with surgery.  Dr. Hansen Yuan, M.D., a leader in spine surgery, added: "This injectable tissue reinforcement procedure can provide an effective treatment for patients who are either early in the disease process or adverse to surgery."

About Intralink-Spine Inc.

Intralink-Spine Inc. (ILS) is privately held by Orthopeutics LP (OLP, Georgetown, TX) and a group of angel investors.  OLP is a biotechnology innovator founded in September of 2004 to develop and commercialize revolutionary non-surgical solutions for common orthopaedic problems.  OLP's general partner is Ampac Biotechnology, Inc. also located in Georgetown, TX.  Ampac was founded in 2001 when it was awarded an STTR Phase I grant from the NIH.

For more information on ILS, please visit: www.intralink-spine.com.

Forward-looking statements

This news release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting ILS's business including increased competition; the ability of ILS to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks.

SOURCE Intralink-Spine Inc.

RELATED LINKS
http://www.intralink-spine.com

'/>"/>

SOURCE Intralink-Spine Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palmer Labs Awarded U.S. Department of Energy Funding for Algae Biofuel Research
2. Prometheus Research Awarded National Science Foundation Grant for Easy to Use, Web-Enabled Database Software
3. Goble & Associates Creative Work Awarded at Advertising Industry Competitions
4. Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project
5. Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases
6. Blue Marble Energy, OPDA Awarded $2M by WAs Community Economic Revitalization Board
7. Daval International Awarded Orphan Drug Designation for Motor Neurone Disease Treatment
8. Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus
9. BioNanomatrix Awarded Supplemental Funding to Accelerate Commercialization of Innovative Single-Molecule Analyzer
10. Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program
11. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... and REYKJAVIK, Iceland , Feb. 28, ... group company and the contract genomics organization enabling precision ... Hannes Smarason has been appointed as the company,s chief executive ... and Alex Fowkes have been named chief ... "WuXi NextCODE is executing on its vision to enable anyone ...
(Date:2/28/2017)... 2017  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical ... of autoimmune diseases, asthma and allergic diseases and ... quarter and full year ended December 31, 2016 ... business and clinical highlights. "During 2016, ... pipeline by starting five clinical trials across our ...
(Date:2/28/2017)... ... February 28, 2017 , ... The ... well as to their processing and transport properties. With the Litesizer™ 100 ... of samples. The Litesizer™ 100 gives rapid and accurate insight into particle systems, ...
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... ... trials, yet requires extensive coordination and expertise. Colpitts Clinical Trial Travel and ... 15 years of meeting this unique need within the biotechnology and pharmaceutical industries ...
Breaking Biology Technology:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
Breaking Biology News(10 mins):